Drugs / 3D011-08
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05099536 | Feb 2022 → Sep 2023 | cancer | 3D Medicines (Beijing) Co., Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3D011-08 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05099536 ↗ |
| Route | Intravenous | “intravenous drop of 3D011-08” NCT05099536 ↗ |